OASMY stock down 98.00% to $0.0001 in market hours: assess valuation vs forecasts
OASMY stock fell 98.00% to $0.0001 during market hours on 30 Jan 2026, trading 1,700 shares on the PNK exchange in the United States. The sharp drop moved market cap to about $6,869.00 and pushed price well below the 50-day average of $0.00530 and the 200-day average of $0.01543. Investors should note an earnings announcement scheduled for 18 Feb 2026 and thin liquidity that amplifies moves. We examine why Vivesto AB (OASMY) is one of today’s top losers and what the data and forecasts imply
Market move and trading data for OASMY stock
Today OASMY stock traded at $0.0001 with a -98.00% one-day change and 1,700 shares traded. Volume was about 27.42 times the 50-day average of 62.00, a signal that the move came on thin, concentrated activity.
The previous close was $0.00500 and the year high remains $0.05. The price collapse shows how low-liquidity ADRs on PNK can swing dramatically on limited order flow.
Company snapshot and catalysts for Vivesto AB (OASMY)
Vivesto AB (OASMY) is a Sweden-headquartered healthcare company focused on oncology drugs, including Apealea and veterinary products. The company is listed as an ADR on the PNK exchange (United States) and reports EPS -0.02, shares outstanding 68,686,398.00, and cash per share $0.02.
Near-term catalysts include the earnings announcement on 18 Feb 2026 and ongoing clinical updates for Docetaxel micellar and Cantrixil. With just 4 full-time employees listed, operational scale and funding remain important risk factors.
Financials and valuation signals
Key metrics show a fragile balance sheet: book value per share $2.23, current ratio 0.38, and operating cash flow per share -$0.52. Price-to-book at current levels is effectively 0.00039, reflecting extreme market discounting versus reported equity.
Earnings per share are negative and the company has no meaningful PE ratio. These figures point to valuation driven by liquidity and expectation rather than recurring revenue.
Technical indicators and liquidity risk
Technicals show mixed signals: RSI 45.66 and ADX 53.31 suggesting a strong trend amid low-price trading. Average volume is 62.00 but today’s volume of 1,700.00 created high relative volume of 27.42, increasing price volatility.
Thin order books on PNK, a year low of $0.0001, and wide gaps between moving averages mean stop orders or modest buys can swing the price sharply. Traders should expect high bid-ask risk and possible trade rejections.
Meyka AI grade and model forecast for OASMY stock
Meyka AI rates OASMY with a score out of 100: 58.79 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, industry metrics, financial growth, key ratios, forecasts, and analyst consensus.
Meyka AI’s forecast model projects a monthly price of $0.01 and a yearly price of $0.03846. Versus the current price $0.0001, that implies an estimated upside of 9,900.00% (monthly) and 38,358.01% (yearly). Forecasts are model-based projections and not guarantees.
Risks, dividend notes and near-term outlook
Risks include low liquidity, weak operating cash flow, and reliance on clinical and regulatory news. The company shows a dividend per share history but dividend calendars offer no recent material company updates source.
Investors should monitor the earnings announcement on 18 Feb 2026 and clinical press releases. For dividend scheduling and payment dates check the dividend calendars and Vivesto corporate releases source.
Final Thoughts
Key takeaways: OASMY stock trades at $0.0001 on PNK with a one-day move of -98.00% and unusual volume of 1,700.00 shares. Fundamentals show negative EPS -0.02, a low current ratio 0.38, and book value per share $2.23, which highlights a disconnect between reported equity and market pricing. Meyka AI rates OASMY 58.79 (Grade C+, HOLD) and flags high risk from liquidity and clinical-dependence. Our forecast model shows a possible monthly level of $0.01 and a yearly projection of $0.03846, implying large percentage gains if those levels materialize; these are model-based and not guarantees. Given the tiny float and ADR listing on PNK, consider position sizing limits, clear exit rules, and monitoring of the Feb 18, 2026 earnings announcement. Meyka AI’s analysis platform provides the data and scenario projections to help investors weigh asymmetric upside projections against high downside and execution risk.
FAQs
Why did OASMY stock fall 98.00% today?
The drop reflects thin liquidity on PNK, concentrated selling and a gap from previous close $0.00500 to $0.0001. No major public corporate catalyst was posted; low float stocks can move sharply on small orders.
What is Meyka AI’s rating for OASMY stock?
Meyka AI rates OASMY 58.79 out of 100, Grade C+, with a suggestion to HOLD. The grade factors in benchmark and sector comparisons, financials, forecasts and analyst signals.
What are realistic price targets for OASMY stock?
Meyka AI’s model projects $0.01 (monthly) and $0.03846 (yearly). These imply large percentage moves versus the current $0.0001 but are model projections, not guarantees.
How should investors manage risk with OASMY stock?
Use strict position sizing, limit orders and stop levels. Watch liquidity, the earnings date 18 Feb 2026, and clinical updates. Expect high volatility on PNK ADR trades.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
